Phase II trial of Loubo® (lobaplatin) and pemetrexed for patients with metastatic breast cancer not responding to anthracycline or taxanes

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 1, 2013, Pages 413-417

  Deng, Qian Qian ^a,b   Huang, Xin En ^a   Ye, Li Hong ^b   Lu, Yan Yan ^a   Liang, Yong ^a,b   Xiang, Jin ^a  

^a JIANGSU CANCER HOSPITAL   (China)

^b NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Clinical trial; Lobaplatin; Metastatic breast cancer.; Pemetrexed

Indexed keywords

EID: 84877105036     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.1.413     Document Type: Article

References (36)

1. Akram M, Siddiqui SA (2012). Breast cancer management: Past, present and evolving. Breast Mini Symposium, 49, 277-282.
2. Bonadonna G, Brusamolino E, Valagussa P, et al (1976). Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med, 294, 405-10.
3. Early Breast Cancer Trialists' Collaborative Group (EBCTCG)(2005). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet, 365, 1687-717.
4. Garin A, Manikhas A, Biakhov M, et al (2008). A phase II study of pemetrexed and carboplatin in patients with locally advanced or metastatic breast cancer. Breast Cancer Res Treat, 110, 309-15.
5. Gao LL, Huang XE, Zhang Q, et al (2011). A Cisplatin and vinorelbine (NP) regimen as a postoperative adjuvant chemotherapy for completely resected breast cancers in China: final results of a phase II clinical trial. Asian Pac J Cancer Prev, 12, 77-80.
6. Gietema JA, de Vries EG, Sleijfer DT, et al (1993). A phase I study of 1, 2-diamminomethyl-cyclobutane-platinum (II)-lactate (D-19466; lobaplatin) administered daily for 5 days.Br J Cancer, 67, 396-401.
7. Gong P, Huang XE, Chen CY, et al (2012). Comparison on complications of peripherally inserted central catheters by ultrasound guide or conventional method in cancer patients. Asian Pac J Cancer Prev, 13, 1873-5.
8. Gu M, Li SY, Huang XE, et al (2012). A Phase II Study on Continuous Infusional Paclitaxel and 5-Fu as First-line Chemotherapy for Patients with Advanced Esophageal Cancer. Asian Pac J Cancer Prev, 13, 5587-91.
9. Huang XE, Li CG, Li Y, et al (2011). Weekly TP regimen as a postoperative adjuvant chemotherapy for completely resected breast cancer in China: final result of a phase II trial. Asian Pac J Cancer Prev, 12, 2797-800.
10. Jiang Y, Huang XE, Yan PW, et al (2010). Validation of treatment efficacy of a computer-assisted program for breast cancer patients receiving postoperative adjuvant chemotherapy. Asian Pac J Cancer Prev, 11, 1059-62.
11. Li CG, Huang XE, Li Y, et al (2011). Clinical observations on safety and efficacy of OxyContin® administered by rectal route in treating cancer related pain. Asian Pac J Cancer Prev, 12, 2477-8.
12. Li CG, Huang XE, Li Y (2011). Phase II trial of irinotecan plus nedaplatin (INP) in treating patients with extensive stage small cell lung cancer. Asian Pac J Cancer Prev, 12, 487-90.
13. Li CG, Huang XE, Xu L, et al (2012). Clinical application of serum tumor associated material (TAM) from non-small cell lung cancer patients. Asian Pac J Cancer Prev, 13, 301-4.
14. Li Y, Yan PW, Huang XE, et al (2011). MDR1 gene C3435T polymorphism is associated with clinical outcomes in gastric cancer patients treated with postoperative adjuvant chemotherapy. Asian Pac J Cancer Prev, 12, 2405-9.
15. Liu W, Li SY, Huang XE, et al (2012). Inhibition of tumor growth in vitro by a combination of extracts from rosa roxburghii tratt and fagopyrum cymosum. Asian Pac J Cancer Prev. 13, 2409-14.
16. Ma CX, Steen P, Rowland KM, et al (2006). A phase II trial of a combination of pemetrexed and gemcitabine in patients with metastatic breast cancer: an NCCTG study. Ann Oncol, 17, 226-31.
17. Martin M, Pienkowski T, Mackey J, et al (2005). Adjuvant docetaxel for node-positive breast cancer. N Engl J Med, 352, 2302-13.
18. Martin M (2006). Clinical experience with pemetrexed in breast cancer. Semin Oncol, 33, S15-8.
19. National Cancer Institute (US) (1998). Common toxicity criteria: index.
20. Robert NJ, Conkling PR, O'Rourke MA, et al (2011).Results of a phase II study of pemetrexed as first-line chemotherapy in patients with advanced or metastatic breast cancer. Breast Cancer Res Treat, 126, 101-8.
21. Sheri A, Johnston S (2013). New developments and future directions in systemic therapy. Clin Oncol (R Coll Radiol), 25, 117-26.
22. Shu J, Li CG, Liu YC, et al (2012). Comparison of serum tumor associated material (TAM) with conventional biomarkers in cancer patients. Asian Pac J Cancer Prev, 13, 2399-403.
23. Song QK, Li J, Jiang HD, et al (2012). Esophageal cancer mortality during 2004-2009 in Yanting County, China. Asian Pac J Cancer Prev, 13, 5003-6.
24. Sudoh J, Gemma A (2008). [Pemetrexed]. Gan To Kagaku Ryoho, 35, 1033-8.
25. Welink J, Boven E, Vermorken JB, Gall HE, van der Vijgh WJ (1999). Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal of liver function. Clin Cancer Res, 5, 2349-58.
26. Xu HX, Huang XE, Li Y, et al (2011). A clinical study on safety and efficacy of Aidi injection combined with chemotherapy. Asian Pac J Cancer Prev, 12, 2233-6.
27. Xu HX, Huang XE, Qian ZY, et al (2011). Clinical observation of Endostar® combined with chemotherapy in advanced colorectal cancer patients. Asian Pac J Cancer Prev, 12, 3087-90.
28. Xu JW, Li CG, Huang XE, et al (2011). Ubenimex capsule improves general performance and chemotherapy related toxicity in advanced gastric cancer cases. Asian Pac J Cancer Prev, 12, 985-7.
29. Xu T, Xu ZC, Zou Q, Yu B, Huang XE (2012). P53 Arg72Pro Polymorphism and Bladder Cancer Risk - Meta- analysis Evidence for a Link in Asians but not Caucasians. Asian Pac J Cancer Prev, 13, 2349-54.
30. Yan PW, Huang XE, Jiang Y, et al (2010). A clinical comparison on safety and efficacy of Paclitaxel/Epirubicin (NE) with Fluorouracil/Epirubicin/Cyclophosphamide (FEC) as postoperative adjuvant chemotherapy in breast cancer. Asian Pac J Cancer Prev, 11, 1115-8.
31. Yan PW, Huang XE, Yan F, et al (2011). Influence of MDR1 gene codon 3435 polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancer. Asian Pac J Cancer Prev, 12, 2291-4.
32. Yao CY, Huang XE, Tang JH, et al (2010). Clinical observationson safety of fixed dose rate gemcitabine chemotherapy by intravenous infusion. Asian Pac J Cancer Prev, 11, 553-5.
33. Yu DS, Huang XE, Zhou JN, et al (2012). Comparative study on the value of anal preserving surgery for aged people with low rectal carcinoma in Jiangsu, China. Asian Pac J Cancer Prev, 13, 2339-40.
34. Zhang LQ, Huang XE, Wang J (2011). The cyclin D1 G870A polymorphism and colorectal cancer susceptibility: a meta-analysis of 20 populations. Asian Pac J Cancer Prev, 12, 81-5.
35. Zhang XZ, Huang XE, Xu YL, et al (2012). Phase II study on voriconazole for treatment of Chinese patients with malignant hematological disorders and invasive aspergillosis. Asian Pac J Cancer Prev, 13, 2415-8.
36. Zhou JN, Huang XE, Ye Z, et al (2009). Weekly paclitaxel/ Docetaxel combined with a paltinum in the treatment of advanced non-samll cell lung cancer: a study on efficacy, safety and pre-medication. Asian Pac J Cancer Prev, 10, 1147-50.